Sweetening the pot: adding glycosylation to the biomarker discovery equation.
Aberrant glycosylation has been recognized for >30 years as a hallmark of cancer (1). However, the complex nature of glycan structure and synthesis has constrained the pace of discoveries relating to their biological significance. Recent advances in carbohydrate chemistry, chemical biology, and mass spectrometry (MS)  techniques have opened the door to rapid progress in correlating glycan structure and function (2-10). At the same time, the maturation of proteomics has put cancer biomarker discovery studies at the top of many to-do lists (11). The confluence of these 2 fields has led many investigators to the same conclusion: Exploiting differences in glycosylation between malignant and healthy tissues likely affords excellent opportunities to identify sensitive and specific cancer biomarkers (12-20). Specifically, as diagrammed in Fig. 1, glycosylation machinery appears to be particularly sensitive to malignant transformation; as a result, the saccharide structures that are added to normal cellular proteins change, resulting in neoglycoforms that can be released from the cell through conventional secretory pathways, or as the result of enhanced proteinase activity. It is possible that a portion of these alternatively glycosylated molecules reach the bloodstream. As such, they could serve as early sentinels that enable cancer detection.
Intriguingly, many of the oldest and most widely used clinical cancer biomarker tests detect glycoproteins. These include carcinoembryonic antigen (CEA), commonly used as a marker of colorectal cancer; cancer antigen 125 (CA-125), frequently used to diagnose ovarian cancer; and prostate-specific antigen (PSA) (14, 21, 22). All of these diagnostic markers are glycoproteins, and the glycans that they present change during oncogenesis (18,23,24). Capitalizing on alterations in cancer-related protein glycoforms affords the possibility of increasing diagnostic sensitivity and specificity. The separation of serum PSA glycoforms by lectins--proteins that specifically bind glycans according to their structural epitopes--highlights this point. The Maackia amurensis agglutinin lectin can distinguish (P < 0.001) between blood samples from individuals with benign prostatic hypertrophy and prostate cancer patients (18), which standard PSA tests fail to do (25).
[FIGURE 1 OMITTED]
Tellingly, several other clinically useful cancer biomarkers directly detect glycan epitopes. CA 19-9 binds to sialyl [Lewis.sup.a] ([sLe.sup.a]) [Sia[alpha]2-3Gal[beta]1-3(Fuc[alpha]1-4)GlcNAc] (26), a terminal epitope that imparts unique biological functions (see Biological Significance of Altered Glycosylation in Cancer for details). Although serum CA 19-9 concentrations are the most commonly used biomarker for diagnosing pancreatic cancer, monitoring treatment efficacy, and detecting recurrence, the current test lacks sensitivity and specificity (27). In this context, it is important to consider that CA 19-9 and related epitopes exhibit genetic variation within the population. For example, the secretor FUT2 [fucosyltransferase 2 (secretor status included) (alias, galactoside 2-[alpha]-L-fucosyltransferase 2)]  and Le FUT3 [fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group)] genes control the expression of enzymes in the synthetic pathway that governs expression of critical antigenic saccharide residues and, thus, an individual's presentation of Le blood group structures (28). Accordingly, depending on their genetic makeup, many populations have high background concentrations of these epitopes present as normal components of serum and other secreted glycoproteins (29, 30). Several groups have proposed including analysis of an individual's secretor and Le blood group status to improve the diagnostic sensitivity and specificity of serum CA 19-9 tests (28, 31). Indeed, 1 study assessed serum CA 19-9 concentrations in 500 healthy individuals and categorized the donors into 6 groups based on FUT2 and FUT3 genotype (28). They observed a 6-fold difference in the upper reference limit (the concentrations of antigen above which disease is suspected) between the groups with the highest and lowest endogenous CA 19-9 production, suggesting the importance of including this information in the analysis.
The prevalence of glycoprotein and glycan cancer biomarkers can be traced to de novo or altered glycan expression by transformed cells (see Fig. 1 and Biological Significance of Altered Glycosylation in Cancer). Detection of these changes at the cytological (e.g., bladder cancer) and histological levels by lectins and glycoreactive antibodies guides disease diagnoses and enables more accurate prognoses. The lectins Helix pomatia agglutinin (HPA), which detects [alpha]-GalNAc [+ or -] [beta]1-4Gal, and Ulex europaeus I agglutinin (UEA 1), which recognizes Fuc[alpha]1-2Gal[beta], are used to assess breast cancer biopsy specimens (32-34). HPA is also part of a panel of markers for histological characterization of gastric cancer specimens (35). In both cases, HPA expression is correlated with increased lymph node metastases, and expression of saccharide sequences that react with either HPA or UEA 1 is related to decreased survival (32-35). Interestingly, many of the most informative tests assess expression of Le antigens. For example, CA 19-9 and other anti-[sLe.sup.a], -[Le.sup.x], -[sLe.sup.x], and -[Le.sup.y] antibodies are used in the evaluation of biopsy specimens from breast, bladder, colorectal, esophageal and non-small cell lung carcinoma (36-43). In all instances, Le antigen expression is correlated with increased metastasis, advanced stage of disease, and reduced survival time.
Thus, it is clear that many of the clinical tests currently used to diagnose and manage the treatment of cancer exploit changes in glycosylation that accompany the disease process. In this context, it is interesting to consider the fact that very few biomarker discovery strategies are designed to focus on this class of posttranslational modifications. One reason may be that the complexity and heterogeneity of carbohydrate structures carried by glycoproteins have made it difficult to understand their functions. As discussed in the next section, recent progress has been made in this important area.
Biological Significance of Altered Glycosylation in Cancer
Cancer-related changes in glycosylation reflect interesting and disease-specific alterations in glycan biosynthetic pathways. These include variations in the expression ofglycosyltransferases, enzymes that add activated donor monosaccharides in specific stereochemistries to acceptors, i.e., growing carbohydrate chains. Expression of enzymes and their corresponding substrates can be downregulated, as is observed with Core 3 O-carbohydrate structures and laminin-binding glycans in gastric and colorectal tumor biopsies or prostate and breast cancer cell lines, respectively (44, 45). Reduction in these glycoforms appears to be related to increased invasive/metastatic potential of carcinoma cells (46). Alternatively, glycan structures can be upregulated in tumors compared with normal cells. For example, UDP-GlcNAc:N-glycan GlcNAc transferase V (GlcNAcT-V), which is involved in branching of N-linked glycans, is overexpressed in numerous cancers (47); the product of this enzyme, which the Phaseolus vulgaris leukoagglutinating lectin detects, is associated with metastasis and decreased survival time in colorectal cancer (48). The upregulation of cell-surface expression of specific monosaccharides is also observed in cancer; prominent examples include increased sialylation and fucosylation. Regarding sialic acid, the sialyltransferases ST3Gal I, which adds N-acetylneuraminic acid (NeuAc) to O-linked galactose (Gal) moieties, and ST6GalNAc I, which adds sialic acid to the Tn antigen (GalNAc[alpha]1-O-Ser/Thr), are both upregulated in breast cancer and are associated with aggressive disease and poor prognosis (49-51). Another sialyltransferase, ST6Gal I, is also reported to be overexpressed in many malignant tumors (52). Regarding fucose, expression of several relevant biosynthetic pathways correlates with cancer. These include the GDP-mannose 4,6-dehydratase, GDP-fucose transporter, and fucosyl transferases FucT-IV and FucTVII, all of which are upregulated to varying degrees in hepatocellular carcinomas compared with normal tissues [reviewed in (53)]. Similarly, increases in the expression of both FucT-IV and the sialyltransferase ST3Gal II are observed in human colorectal cancer biopsy specimens compared with adjacent noncancerous tissue (54).
Members of the matrix metalloproteinase (MMP) and ADAM (a disintegrin and metalloproteinase) families are another important class of molecules that are upregulated in malignant tissues (55, 56). These degradative enzymes cleave proteins and glycoproteins from the cell surface and the adjacent extracellular matrix (ECM), often altering cellular behavior and stromal signals, respectively. In aggregate, these changes are thought to facilitate the growth and metastasis of tumor cells. For example, "ectodomain shedding" releases and activates plasma membrane-associated molecules such as epidermal growth factor (EGF). These alterations afford several clinical applications; e.g., high MMP expression correlates with adverse outcomes in breast, gastric, pancreatic, and prostate cancers (57, 58). Their glycan-containing products, which have important biological activities, can also be exploited for diagnostic purposes. Thus, tumor-associated enhanced proteinase activity increases the likelihood that molecules carrying these neoglycans will be identified in the surrounding tissue compartment, where they may eventually enter the circulation (Fig. 1 and following sections).
Cancer-related changes in glycan biosynthesis and proteinase activity have enormous biological ramifications, many of which advance tumor formation and disease progression. For instance, some carbohydrate modifications seem to act as "molecular switches" affecting glycan conformation and thus lectin binding. In this context, cancer-related substitutions, including sialylation and core fucosylation, govern myriad functions (e.g., serum clearance and hepatic uptake) (59). Additionally, upregulation of MMPs/ADAMs and presentation of cancer-related glycans generally decrease cell-cell and cell-ECM adhesion and promote migration (56, 60). Regulation of integrin function appears to play a key role in these processes. Integrins are heterodimeric adhesion molecules that mediate cell interactions with ECM substrates such as fibronectin and laminin, and with cell-surface proteins such as vascular cell adhesion molecule (61). As a group, integrins are highly N-glycosylated, with some dimers, e.g., [alpha]5[beta]1 and [alpha]3[beta]1, possessing a total of 26 potential N-linked glycosylation sites (62).
Numerous aspects of integrin biology--including expression, heterodimerization, ligand binding, and downstream signaling--are modulated by glycosylation (63). A minimal glycan repertoire allows cellsurface expression of these heterodimers; further elaborations to glycan structure refine integrin function. For instance, increased integrin sialylation, mediated by the glycosyltransferase ST6Gal I, leads to integrin activation, increased adhesion to ECM substrates, and augmented migration and invasion of colon cancer cell lines in vitro (52, 64). Similarly, in vivo, ST6Gal I expression by spontaneously derived mouse mammary tumors modulates integrin signaling and tumor differentiation (65). In addition to sialylation, integrins are also modified by the glycosyltransferase GlcNAcT-V and, as a result, carry highly branched structures (47). Spontaneous mammary tumors, which developed in a GlcNAcT-V-deficient mouse model, exhibited decreased growth, metastasis, and signaling downstream ofthe focal adhesion kinase, evidence that the observed effects are mediated, in part, by loss of integrin-associated N-linked branching (47).
The highly branched GlcNAcT-V glycan products are often further elaborated with the addition of polylactosamine chains, polymeric repeating units of galactose and N-acetylglucosamine (i.e., lactosamines). Galectins, a family of endogenous lectins, bind these epitopes. Galectins can multimerize through homotypic interactions, forming a lattice-type network that incorporates glycosylated ligands and other galectin molecules (66). This architecture stabilizes bound cell-surface molecules, preventing lateral movements and endocytosis. Thus, this phenomenon can affect many processes. GlcNAcT-V regulates tumor motility, in part, through galectin-3 binding to newly presented lactosamine sequences, and the consequences include changes in integrin signaling (67). GlcNAcT-V also modifies N-linked glycans on receptor tyrosine kinases such as EGF receptor (EGFR) and transforming growth factor [beta] receptors I and II (T[beta]RI and II). Upon polylactosaminylation, they become ligands for galectin-3, which leads to lattice formation and receptor entrapment. The lattice helps the cell surface receptors resist removal by constitutive endocytosis, and thus increases receptor signaling (68). EGFR is highly N-glycosylated, whereas T[beta]RI and T[beta]RII carry minimal modifications. Accordingly, cells display a strong GlcNAcT-V-dependent response when ligands bind to the former receptor, and less so when the latter receptors become engaged (68). Interestingly, GlcNAcT-V also plays a role in epithelial to mesenchymal transitions (68), an early stage of oncogenesis that is correlated with metastasis (69). This effect might be mediated, in part, through GlcNAcT-V influences on integrin and growth factor receptor signaling.
Metastasis is a critical event in the progression of tumor development. This multistep process begins when individual primary tumor cells breach the basement membrane and access the local vasculature, where they interact with endothelial cells, platelets, and leukocytes (70, 71). Exit from the circulation is accomplished by extravasation, which requires a series of steps. This shear stress-dependent process begins with rolling on endothelial cells, which leads to tethering and integrin-dependent stable adhesion. It is thought that extravasation occurs at receptive sites primed by circulating tumor-derived factors. Successful metastasis requires coordinated interactions between the newly engrafted tumor cell, the "seed," and the "soil" at sites of metastasis (70, 71).
The first step of extravasation, rolling of cells along the endothelium, is regulated by glycosylation. Specifically, rolling is mediated by adhesion under shear stress of the selectin family of endogenous lectins to their carbohydrate ligands on cell-surface glycoproteins. The selectin family consists of 3 members that exhibit differential expression patterns. Endothelial cells display E-selectin and P-selectin, platelets express P-selectin, and leukocytes present L-selectin (72, 73). Carbohydrate ligands for selectins are modified Le blood group antigens, i.e., contain fucosylated and sialylated epitopes. These structures, detectable by antibodies such as CA19-9 (26), are abundant in malignant tissues, where their expression is strongly correlated with metastasis and poor disease outcome (see Clinical Tests Based on Cancer-Related Changes in Glycosylation above). It is thought that tethering and rolling of tumor cells occurs through selectin-mediated interactions between malignant cells and the endothelium (via E- and P-selectin). However, interactions between malignant cells and circulating platelets and leukocytes (via P- and L-selectins, respectively) are also thought to participate in tumor cell extravasation. One model envisions that circulating aggregates of tumor cells, platelets, and/or leukocytes form microvascular occlusions that arrest the cells, providing a possible means of egress from the vessel (70, 73). Thus, although expression patterns vary by virtue of location and carbohydrate selectivity, each selectin family member is poised to influence tumor metastasis.
Evidence is accumulating that the clinical correlation observed between tumor expression of selectin ligands and metastasis (see Clinical Tests Based on Cancer-Related Changes in Glycosylation) is a reflection of a causal relationship (74). Mice lacking L-selectin, P-selectin, or both molecules, exhibit greater resistance to the metastasis of colon carcinoma cells (75, 76). E-selectin is also implicated in tumor metastasis. Notably, 1 study followed dissemination of melanoma tumor cells, either presenting or lacking E-selectin ligands, in a mouse model in which E-selection was overexpressed in the liver. Tumor cell expression of E-selectin ligands was required for metastasis to the liver of transgenic but not wild-type mice (77). Thus, the pattern of E-selectin expression governs metastasis, a finding that has interesting implications for the pathogenesis of human cancers. Additionally, cancer-related protein scaffolds have been identified as selectin-ligand carriers, and thus as participants in the extravasation process. For instance, CEA, the glycoprotein commonly used as a marker for colorectal cancer (Clinical Tests Based on Cancer-Related Changes in Glycosylation above), and CD44, a highly glycosylated cell-surface adhesion protein, can serve as E- and L-selectin ligands (74).
In summary, the examples in this section illustrate the biological importance of glycosylation to tumor development and disease progression. As biomarker discovery becomes more sophisticated, it is clear that using glycobiology to inform experimental design will lead to more sensitive and specific diagnostic tests (78, 79). In this context, cancer-related changes in glycosylation can guide biomarker studies. As discussed in the next section, many laboratories have already begun exploring approaches to exploit the latest technological and biological breakthroughs in these areas.
Current Approaches to Glycan-Based Biomarker Discovery
The challenge of biomarker discovery is to identify the disease-related needle in the haystack of normally expressed proteins. Although several accessible human fluids, including urine and saliva, are available for biomarker studies, the subject of the majority of biomarker discovery approaches to date--and the one with the highest order of complexity--is processed blood (as plasma or serum). In this context, the normal plasma or serum proteome/glycome is the haystack, which creates a myriad of background issues. In this regard, it is noteworthy that 82 of the 100 most abundant plasma proteins are glycoproteins (see Supplemental Table 1, which accompanies the online version of this article at http://www.clinchem.org/content/vol56/issue2) (80). However, the majority ofthese endogenous molecules carry basic glycan motifs lacking typical cancer-related structures, including fucosylation, sialylation, more complex N-linked branching, and polylactosaminylation. Thus, judicious selection of lectins or antibodies that recognize carbohydrate epitopes for capture of cancer-related glycoforms enables separation of potential biomarker targets. The list of potentially useful lectins and antibodies shown in Table 1 demonstrates the versatility of these tools for identifying structural differences.
Given that affinity selection is the hallmark of workflows that are designed to capture glycan-containing molecules, it is possible to analyze unfractionated samples. However, many investigators commonly include immunoaffinity depletion of the most abundant proteins, which enables deeper coverage of the remaining lower-abundance proteome where biomarkers typically reside. Multiple platforms have been employed for this purpose, including ProteomeLab IgY (Beckman Coulter; www.beckmancoulter.com), Seppro IgY and SuperMix (Sigma-Aldrich; www.sigmaaldrich. com) (81), and the Multiple Affinity Removal System (Agilent Technologies; www.agilent.com) (81-83).
Current glycan-based biomarker approaches typically involve 1 or more enrichment steps, proteolytic digestion, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) analyses. Enrichment of carbohydrate-containing species is performed at either the glycoprotein or glycopeptide level, with distinct rationales for each strategy. Major advantages of performing affinity selection at the glycoprotein level include the increased likelihood of obtaining sequence information from multiple peptides, which in turn facilitates glycoprotein identification (84). Disadvantages of this approach, which are overcome by selecting at the glycopeptide level, include a higher probability of nonspecific protein-protein interactions, a particular concern since manylectins are hydrophobic molecules (85).
Compared with their O-linked counterparts, N-linked glycopeptides are more commonly analyzed in glycan-based biomarker workflows, as they are amenable to peptide N-glycosidase F (PNGase F) digestion, which hydrolyzes the amide bond of the asparagine residue to which the glycan is attached (86). This reaction results in a 1-Da molecular mass increase in the deglycosylated form of the peptide. Additional certainty is gained by requiring that this mass shift be observed in the context of an N-linked consensus sequence (NXT/S, where X is any residue except proline). Because PNGase F is an asparagine deamidase, it is also possible to enzymatically incorporate oxygen-18 at the site of glycan release (87). The development of equivalent enzymes for the release of O-linked structures, and identification of their sites of attachment, have yet to be achieved. In this regard, it may be possible to engineer a proteinase that can hydrolyze the GalNAc-Ser/Thr linkage.
Lectin- and Antibody-Based Affinity Selection
A variety of protocols have been developed for lectin capture of glycoproteins and glycopeptides. These include using single lectins (82, 84, 88) as well as mixtures, e.g., concanavalin A, wheat germ agglutinin, and Artocarpus integrifolia (jacalin). The latter approach has been dubbed multilectin affinity chromatography (89-92). Less commonly, carbohydrate-reactive antibodies such as those recognizing Le blood group antigens (Table 1) are used for enrichment (93). Additional lectin-capture steps and dimensions of fractionation (e.g., hydrophilic interaction, ion exchange, reversed-phase chromatography) have been used in series to achieve greater protein and peptide coverage (82, 84, 87, 89-91, 93). Elution methods include displacement by specific mono- or disaccharide solutions (88, 89, 94) or by high-salt and/or acidic conditions (84, 93, 95). Numerous workflows use commercially available agarose-conjugated lectins in a centrifugal, gravityflow, or low-pressure HPLC format (84, 89, 92, 93). Magnetic bead technology has also been used (95, 96). When desirable, a higher degree of reproducibility and speed is achieved by using lectins conjugated to HPLC-compatible matrices (83, 88), which enable high-pressure/high-flow-rate chromatography.
In general, glycoprotein/glycopeptide enrichment methods identify fewer proteins than in-depth protein analyses. For instance, in 4 studies involving lectin or antibody glycoprotein/glycopeptide capture and reversed-phase LC-MS/MS analyses, 25-150 glycoproteins were observed (84, 89, 93, 94). As expected, the inclusion of additional separation steps often increases the number of proteins identified. Including a third dimension of separation and/or depletion of abundant proteins enabled identification of 50-250 glycoproteins (82, 87, 89, 94). Interestingly, narrow-specificity lectins that recognize disease-related carbohydrate structures capture fewer plasma proteins than do those with broader specificities, making them attractive affinity selectors for isolating cancer-related glycosylated biomarkers. Jung et al. (84) observed that concanavalin A, which has broad reactivity for the mannose cores typically found in N-linked glycans, captured approximately 30% of the plasma proteome. In contrast, a panel of lectins with narrower specificities bound a much smaller fraction. Two fucose-specific lectins, Aleuria aurantia lectin (AAL) and Lens culinaris agglutinin (LCA), bound approximately 4% and 8% of plasma proteins, respectively; Lycopersicon esculentum lectin (LEL), which targets polylactosamine, and HPA (see Clinical Tests Based on Cancer-Related Changes in Glycosylation) selected [less than or equal to] 0.1% of the proteins contained in plasma.
Several studies have applied glycan-based enrichment strategies to cancer biomarker discovery. In general, these studies tend to be small-scale proof-of-principle endeavors. It is noteworthy that, on the whole, they have succeeded in identifying target biomarker candidates for further validation. The published literature suggests that focusing the selection process on cancer-relevant glycans increases the likelihood ofidentifying potential disease targets. For example, in 1 study, approximately 10% of the proteins that bound to HPA and LEL were increased in abundance by at least 3-fold in samples obtained from breast cancer patients compared with control subjects (84). Comunale et al. (82) used AAL to enhance recovery of fucosylated glycoproteins from pooled serum samples obtained from 3 study groups: patients with liver cirrhosis with or without hepatocellular carcinoma and healthy control subjects. Approximately 50 glycoproteins tracked with the hepatocellular carcinoma diagnosis, and a subset were validated in a cohort of 332 patients using an antibody-lectin sandwich array (discussed in Strategies to Exploit Cancer-Related Glycobiology for Developing Diagnostic Tests). From these studies, fucosylated hemopexin emerged as a potential biomarker with a specificity and sensitivity of 92% (82).
Chemical biology presents numerous approaches to enrich glycosylated molecules by exploiting glycan structures and manipulating their biosynthetic pathways (97). Two similar approaches, involving hydrazide or boronic acid chemistry, capitalize on the cis-diols present in monosaccharides. Zhang et al. (98) pioneered the use of hydrazide chemistry for purification by directly coupling glycosylated proteins to a solid support. In this scheme, carbohydrate cis-diols are oxidized into aldehydes by sodium periodate treatment, then covalently coupled through hydrazide chemistry to functionalized beads. Bound glycoproteins are trypsin-digested in situ, and nonglycosylated/ unbound peptides are removed bywashing. Covalently coupled N-linked glycoproteins are then released by PNGase F treatment and analyzed by LC-MS/MS. Using this approach, the authors identified 57 serum glycoproteins. The same laboratory published a revised version of this method that captures glycopeptides rather than intact glycoproteins (99). This modified procedure markedly improved glycopeptide recovery to >90%. In the aggregate, approximately 300 unique glycosylation sites were observed in serum samples and tissue lysates. A similar method was used by Sun et al. (100), who identified 302 proteins from an ovarian cancer cell line with 91% selectivityfor N-linked glycopeptides in the captured fractions. A complementary approach was devised by Sparbier et al. (101), who used boronic acid-functionalized beads to covalently capture (through formation of heterocyclic boronic acid diesters) glycoproteins followed by elution with acid. This method was recently applied to the analysis of serum samples: 113 proteins were identified, of which 74 were known or proposed glycoproteins (102). Other captured molecules included proteins known to associate with glycoproteins, suggesting that this method may also be useful for characterizing complexes that contain glycosylated molecules. Building on data derived from these methods, Aebersold's group (103) developed a searchable online catalog for depositing data regarding N-linked glycosylation sites and glycopeptide sequences (www.UniPep.org). This repository is an important companion to sequence-based algorithms that predict N-linked glycosylation sites, and as such is a valuable resource for plasma- and serum-based studies. Finally, hijacking glycan biosynthetic pathways for the incorporation of monosaccharides bearing bioorthogonal functional handles affords an alternative approach to chemically labeling glycoconjugates (104).
Whereas the above-described biomarker approaches strive to identifydisease-related glycoproteins, another method targets the glycans themselves as cancer biomarkers. This approach involves the enzymatic or chemical release of N- and O-linked glycans from biological sources (e.g., cancer cell lines, tumors, or plasma/serum), followed by MS-based characterization and identification of cancer-related glycoforms. Studies using these techniques identified distinct glycan subsets that correlated with malignant versus nontransformed cell lines, or that were preferentially expressed by cancer cell lines derived from specific tissues (105, 106).Lietal. (107) used gel electrophoresis to separate proteins from medium that was conditioned by cancer cell lines or serum from individuals with ovarian cancer. Glycoprotein-containing bands, which were identified by virtue of their reactivity with Pro-Q Emerald 300, were isolated, and the attached carbohydrates were characterized by MS. The results yielded information about glycan structures that were unique to the disease state. Interestingly, investigators used specific serum glycoforms to distinguish individuals with prostate or ovarian cancer from those without disease (108, 109). A study by Kirmizet al. (110) demonstrated a successful progression of inquiry that began with analysis of glycans released from a panel of breast cancer cell lines. The study next moved into a mouse mammary tumor model, where cancer-related glycans were observed in serum at various time points over a 6-week course of disease progression. Finally, a small number of serum samples were analyzed from healthy control subjects and patients with breast cancer. Remarkably, the molecular ions corresponding to glycans observed in breast cancer cell lines and serum samples of mice with mammary tumors were also present in patient sera.
Strategies to Exploit Cancer-Related Glycobiology for Developing Diagnostic Tests
The use of glycobiology to inform biomarker studies holds clear promise for the rapid identification of disease markers that enable risk prediction as well as diagnosis, prognosis, and monitoring response to therapy. If recent trends prevail, it is highly likely that future biomarker discovery efforts will focus on developing panels of disease sentinels, rather than pursuing single molecules. This change in strategy has been driven by a better understanding of the inherent complexity of human biology, which has in turn highlighted the importance of patient-specific therapies. In this context, approaches that allow the simultaneous analysis of numerous markers, or multiplexing, are highly advantageous.
At present, 2 relatively new technology platforms are particularly suited for the analysis of cancer-related neoglycans. The first is multiple reaction monitoring (MRM), an MS-based approach. MRM achieves high analytical specificity and sensitivity by selecting predetermined precursor molecular ions for collision-induced dissociation and monitoring the appearance of several diagnostic product ions. When identified in combination, the precursor and product ions confirm the presence of the analyte of interest. Importantly, addition of isotopically labeled internal standards allows absolute quantification. Numerous precursor ions can be monitored in 1 experiment, particularly when using scheduled MRMs, which incorporate prior knowledge of peptide elution times into the LC-MS/MS program (111, 112). Recently, a large National Cancer Institute-sponsored interlaboratory study showed that an MRM approach can quantify target proteins in a background of unfractionated human plasma with highly robust and reproducible results, supporting the notion that this technology is suitable for biomarker discovery (113).
The immediate challenge is to increase the sensitivity of these assays to reach the depth of coverage that will be required to identify molecules in the range of abundances in which disease-specific biomarkers likely circulate. In this regard, the stable isotope standards and capture by antipeptide (or anticarbohydrate) antibodies (SISCAPA) approach is designed to enhance the sensitivity of MRM assays. First reported by Anderson et al. (114), this technique uses antibodies to capture target analytes, followed by elution in a small volume for simultaneous enrichment and concentration. When coupled to an MRM readout, SISCAPA improves the limit of detection byup to 3 orders of magnitude over the original assay (115). Thus, a SISCAPA-MRM approach allows detection by MS of biomolecules present in blood at or near concentrations typical of disease biomarkers (e.g., ng/L to [micro]g/L) with a sensitivity approaching that of clinical immunoassays (115, 116). Interestingly, Aebersold and colleagues (112) reached a similar level of plasma glycoprotein detection and quantification by using hydrazid-emediated capture of carbohydrate-containing molecules followed by release of N-linked glycopeptides and detection by scheduled MRM.
Second, other technologies are being developed that do not require the use of the sophisticated instruments and computer software programs that mass spectrometry entails. For example, lectin-antibody sandwich arrays can be used at every stage in the biomarker discovery and verification pipeline. These assays differentiate disease-associated glycosylation, offer a high level of sensitivity and specificity, and are easily multiplexed. Similar in design to an ELISA, the sandwich assay, in separate steps, detects the protein portion of the analyte (via antibodies) and the attached glycan (via lectins and carbohydrate-specific antibodies). Chen et al. (117) used this method to identify cancer-related changes in glycosylation on mucin-1 (MUC1) and CEA in sera from individuals with pancreatic cancer. In a subsequent study, sandwich arrays were used to monitor changes in glycosylation of mucins expressed by human pancreatic cancer cell lines in response to inflammatory stimuli (118).
Conclusions: The Sweet Future of Cancer Biomarkers
In a recent editorial, a group of distinguished glycobiologists dubbed this the "Second Golden Age of Glycomics" owing to the increasing evidence that disease-related changes in glycosylation will provide the basis for improved cancer biomarkers (79) As shown in Fig. 1, we think that the products of glycosylation, which are often altered in the setting of cancer, are particularly interesting targets that offer several major advantages over proteins. First, the biology allows for the rational design of discovery efforts. For example, changes in the glycosylation machinery can be identified from microarray data and translated in structural terms. In this regard, the glycosyltransferases upregulated in the cancer cell compared with its normal counterpart point to specific disease-related aberrations in oligosaccharide structures. In turn, these observations provide a compelling rationale for designing antibody and lectin-based separation strategies for their isolation in the discoveryphase of biomarker-type projects. Second, 1 protein can carry many copies of an altered glycan, which may also be added to other scaffolds. Thus, there is an important amplification effect, which could enable the detection of many fewer abnormal cells than would otherwise be possible. Finally, glycosylation acts to shield the peptide backbone from proteolytic degradation. Thus, in theory, glycan-based biomarkers are likely to be more stable in a variety of disease settings than unmodified proteins, which are often more labile.
In this context, it is interesting to note that 109 diagnostic tests currently approved by the US Food and Drug Administration measure protein concentration alone, whereas 18 additional assays include assessment of posttranslational modifications. Of the latter subset, 6 assays detect carbohydrate structures (119), namely Lens culinaris agglutinin-reactive [alpha]-fetoprotein, glycated forms of albumin, bone-specific alkaline phosphatase, LDL, CA 19-9, and carbohydrate-deficient transferrin. Notably, while the currentlyapproved clinical tests monitor single biomolecules in isolation, future diagnostics will include multiplexed analyses of numerous proteins with or without their posttranslational modifications or exclusively glycans. In parallel with the shift toward biology-driven discovery efforts, technological improvements in MS platforms and lectin-antibody array methodologies are opening the door to a new generation of approaches for verification and clinical deployment. In total, the confluence of these changes will strongly affect the way cancer is diagnosed and disease progression/remission is monitored in the context of patient-specific therapies.
Author Contributions: All authors confirmed they have contributed to the intellectual content of this paper and have met the following 3 requirements: (a) significant contributions to the conception and design, acquisition of data, or analysis and interpretation of data; (b) drafting or revising the article for intellectual content; and (c) final approval of the published article.
Authors' Disclosures of Potential Conflicts of Interest: Upon manuscript submission, all authors completed the Disclosures of Potential Conflict of Interest form. Potential conflicts of interest:
Employment or Leadership: F.E. Regnier, Purdue University and Quadraspec; B.W. Gibson, Oregon State University, University of Iowa, and Rockefeller University.
Consultant or Advisory Role: F.E. Regnier, Quadraspec.
Stock Ownership: F.E. Regnier, BG Medicine, Quadraspec, and Predictive Physiology and Medicine.
Honoraria: B.W. Gibson, Oregon State University.
Research Funding: Clinical Proteomic Technologies for Cancer initiative, 5U24CA126477-04. A. Prakobphol, NIH; F.E. Regnier, National Cancer Institute; B.W. Gibson, NIH.
Expert Testimony: F.E. Regnier, Pharmacia versus Genentech on Human Growth Hormone.
Other Remuneration: F.E. Regnier, The German Chemical Society (travel to HPLC 2009 in Dresden, Germany).
Role of Sponsor: The funding organizations played no role in the design of study, choice of enrolled patients, review and interpretation of data, or preparation or approval of manuscript.
(1.) Meezan E, Wu HC, Black PH, Robbins PW. Comparative studies on the carbohydrate-containing membrane components of normal and virus-transformed mouse fibroblasts. II. Separation of glycoproteins and glycopeptides by Sephadex chromatography. Biochemistry 1969;8:2518-24.
(2.) Backstrom M, Thomsson KA, Karlsson H, Hansson GC. Sensitive liquid chromatography-electrospray mass spectrometry allows for the analysis of the O-glycosylation of immunoprecipitated proteins from cells or tissues: application to MUC1 glycosylation in cancer. J Proteome Res 2009;8:538-45.
(3.) Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, et al. Detecting glycan cancer biomarkers in serum samples using MALDI FT-ICR mass spectrometry data. Bioinformatics 2009;25:251-7.
(4.) Goldberg D, Bern M, Parry S, Sutton-Smith M, Panico M, Morris HR, Dell A. Automated N-glycopeptide identification using a combination of single- and tandem-MS. J Proteome Res 2007;6:3995-4005.
(5.) Harvey DJ. Structural determination of N-linked glycans by matrix-assisted laser desorption/ionization and electrospray ionization mass spectrometry. Proteomics 2005;5:1774-86.
(6.) Laughlin ST, Bertozzi CR. Imaging the glycome. Proc Natl Acad Sci USA 2009;106:12-7.
(7.) North SJ, Hitchen PG, Haslam SM, Dell A. Mass spectrometry in the analysis of N-linked and O-linked glycans. Curr Opin Struct Biol 2009;19: 498-506.
(8.) Royle L, Campbell MP, Radcliffe CM, White DM, Harvey DJ, Abrahams JL, et al. HPLC-based analysis of serum N-glycans on a 96-well plate platform with dedicated database software. Anal Biochem 2008;376:1-12.
(9.) Tang H, Mechref Y, Novotny MV. Automated interpretation of MS/MS spectra of oligosaccharides. Bioinformatics 2005;21 Suppl 1:i431-9.
(10.) Werz DB, Seeberger PH. Carbohydrates as the next frontier in pharmaceutical research. Chemistry 2005;11:3194-206.
(11.) Wong SC, Chan CM, Ma BB, Lam MY, Choi GC, Au TC, et al. Advanced proteomic technologies for cancer biomarker discovery. Expert Rev Proteomics 2009;6:123-34.
(12.) Barrabes S, Pages-Pons L, Radcliffe CM, Tabares G, Fort E, Royle L, et al. Glycosylation of serum ribonuclease 1 indicates a major endothelial origin and reveals an increase in core fucosylation in pancreatic cancer. Glycobiology 2007;17: 388-400.
(13.) Kuzmanov U, Jiang N, Smith CR, Soosaipillai A, Diamandis EP. Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol Cell Proteomics 2009;8:791-8.
(14.) Meany DL, Zhang Z, Sokoll LJ, Zhang H, Chan DW. Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns. J Proteome Res 2009;8:613-9.
(15.) Misonou Y, Shida K, Korekane H, Seki Y, Noura S, Ohue M, Miyamoto Y. Comprehensive clinicoglycomic study of 16 colorectal cancer specimens: elucidation of aberrant glycosylation and its mechanistic causes in colorectal cancer cells. J Proteome Res 2009;8:2990-3005.
(16.) Mizuochi T, Nishimura R, Derappe C, Taniguchi T, Hamamoto T, Mochizuki M, Kobata A. Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma: appearance of triantennary sugar chains and unique biantennary sugar chains. J Biol Chem 1983;258:14126-9.
(17.) Moore A, Medarova Z, PotthastA, Dai G. In vivo targeting of underglycosylated MUC-1 tumor antigen using a multimodal imaging probe. Cancer Res 2004;64:1821-7.
(18.) Ohyama C, Hosono M, Nitta K, Oh-eda M, Yoshikawa K, Habuchi T, et al. Carbohydrate structure and differential binding of prostate specific antigen to Maackia amurensis lectin between prostate cancer and benign prostate hypertrophy. Glycobiology 2004;14:671-9.
(19.) Peracaula R, Tabares G, Royle L, Harvey DJ, Dwek RA, Rudd PM, de Llorens R. Altered glycosylation pattern allows the distinction between prostate-specific antigen (PSA) from normal and tumor origins. Glycobiology 2003;13:457-70.
(20.) Taylor AD, Hancock WS, Hincapie M, Taniguchi N, Hanash SM. Towards an integrated proteomic and glycomic approach to finding cancer biomarkers. Genome Med 2009;1:57.
(21.) Hammarstrom S. The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues. Semin Cancer Biol 1999;9:67-81.
(22.) Moss EL, Hollingworth J, Reynolds TM. The role of CA125 in clinical practice. J Clin Pathol 2005; 58:308-12.
(23.) Jankovic MM, Milutinovic BS. Glycoforms of CA125 antigen as a possible cancer marker. Cancer Biomark 2008;4:35-42.
(24.) van Gisbergen KP, Aarnoudse CA, Meijer GA, Geijtenbeek TB, van Kooyk Y. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin. Cancer Res 2005;65:5935-44.
(25.) Vashi AR, Wojno KJ, Henricks W, England BA, Vessella RL, Lange PH, et al. Determination of the "reflex range" and appropriate cutpoints for percent free prostate-specific antigen in 413 men referred for prostatic evaluation using the AxSYM system. Urology 1997;49:19-27.
(26.) Magnani JL, Nilsson B, Brockhaus M, Zopf D, Steplewski Z, Koprowski H, Ginsburg V. A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II. J Biol Chem 1982;257:14365-9.
(27.) Orntoft TF, Vestergaard EM. Clinical aspects of altered glycosylation of glycoproteins in cancer. Electrophoresis 1999;20:362-71.
(28.) Vestergaard EM, Hein HO, Meyer H, Grunnet N, Jorgensen J, Wolf H, Orntoft TF. Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population. Clin Chem 1999;45:54-61.
(29.) Prakobphol A, Boren T, Ma W, Zhixiang P, Fisher SJ. Highly glycosylated human salivary molecules present oligosaccharides that mediate adhesion of leukocytes and Helicobacter pylori. Biochemistry 2005;44:2216-24.
(30.) Serpa J, Almeida R, Oliveira C, Silva FS, Silva E, Reis C, et al. Lewis enzyme (alpha1-3/4 fucosyltransferase) polymorphisms do not explain the Lewis phenotype in the gastric mucosa of a Portuguese population. J Hum Genet 2003;48: 183-9.
(31.) Narimatsu H, Iwasaki H, Nakayama F, Ikehara Y, Kudo T, Nishihara S, et al. Lewis and secretor gene dosages affect CA19-9 and DU-PAN-2 serum levels in normal individuals and colorectal cancer patients. Cancer Res 1998;58:512-8.
(32.) Brooks SA, Leathem AJ. Prediction of lymph node involvement in breast cancer by detection of altered glycosylation in the primary tumour. Lancet 1991;338:71-4.
(33.) Fenlon S, Ellis IO, Bell J, Todd JH, Elston CW, Blamey RW. Helix pomatia and Ulex europeus lectin binding in human breast carcinoma. J Pathol 1987;152:169-76.
(34.) Fukutomi T, Itabashi M, Tsugane S, Yamamoto H, Nanasawa T, Hirota T. Prognostic contributions of Helix pomatia and carcinoembryonic antigen staining using histochemical techniques in breast carcinomas. Jpn J Clin Oncol 1989;19: 127-34.
(35.) Kakeji Y, Maehara Y, Tsujitani S, Baba H, Ohno S, Watanabe A, Sugimachi K. Helix pomatia agglutinin binding activity and lymph node metastasis in patients with gastric cancer. Semin Surg Oncol 1994;10:130-4.
(36.) Friedrich MG, Hellstern A, Hautmann SH, Graefen M, Conrad S, Huland E, Huland H. Clinical use of urinary markers for the detection and prognosis of bladder carcinoma: a comparison of immunocytology with monoclonal antibodies against Lewis X and 486p3/12 with the BTA STAT and NMP22 tests. J Urol 2002;168: 470-4.
(37.) Nakagoe T, Fukushima K, Nanashima A, Sawai T, Tsuji T, Jibiki M, et al. Expression of Lewis(a), sialyl Lewis(a), Lewis(x) and sialyl Lewis(x) antigens as prognostic factors in patients with colorectal cancer. Can J Gastroenterol 2000;14: 753-60.
(38.) Narita T, Funahashi H, Satoh Y, Watanabe T, Sakamoto J, Takagi H. Association of expression of blood group-related carbohydrate antigens with prognosis in breast cancer. Cancer 1993; 71:3044-53.
(39.) Ogawa J, Sano A, Inoue H, Koide S. Expression of Lewis-related antigen and prognosis in stage I non-small cell lung cancer. Ann Thorac Surg 1995;59:412-5.
(40.) Ohyama C. Glycosylation in bladder cancer. Int J Clin Oncol 2008;13:308-13.
(41.) Pode D, Golijanin D, Sherman Y, Lebensart P, Shapiro A. Immunostaining of Lewis X in cells from voided urine, cytopathology and ultrasound for noninvasive detection of bladder tumors. J Urol 1998;159:389-92; discussion 93.
(42.) Steplewska-Mazur K, Gabriel A, Zajecki W, Wylezol M, Gluck M. Breast cancer progression and expression of blood group-related tumor-associated antigens. Hybridoma 2000;19:129-33.
(43.) Tauchi K, Kakudo K, Machimura T, Makuuchi H, Mitomi T. Immunohistochemical studies of blood group-related antigens in human superficial esophageal carcinomas. Cancer 1991;67: 3042-50.
(44.) Bao X, Kobayashi M, Hatakeyama S, Angata K, Gullberg D, Nakayama J, et al. Tumor suppressor function of laminin-binding alpha-dystroglycan requires a distinct beta3-N-acetylglucosaminyltransferase. Proc Natl Acad Sci USA 2009;106:12109-14.
(45.) Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, et al. Core 3 synthase is downregulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA 2005;102: 4572-7.
(46.) Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, et al. Core3 O-glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through down-regulation of alpha2beta1 integrin complex. J Biol Chem 2009;284:17157-69.
(47.) Granovsky M, Fata J, Pawling J, Muller WJ, Khokha R, Dennis JW. Suppression of tumor growth and metastasis in Mgat5-deficient mice. Nat Med 2000;6:306-12.
(48.) Seelentag WK, Li WP, Schmitz SF, Metzger U, Aeberhard P, Heitz PU, Roth J. Prognostic value of beta1,6-branched oligosaccharides in human colorectal carcinoma. Cancer Res 1998;58: 5559-64.
(49.) Burchell J, Poulsom R, Hanby A, Whitehouse C, Cooper L, Clausen H, et al. An alpha2,3 sialyltransferase (ST3Gal I) is elevated in primary breast carcinomas. Glycobiology 1999;9:1307-11.
(50.) Leivonen M, Nordling S, Lundin J, von Boguslawski K, Haglund C. STn and prognosis in breast cancer. Oncology 2001;61:299-305.
(51.) Sewell R, Backstrom M, Dalziel M, Gschmeissner S, Karlsson H, Noll T, et al. The ST6GalNAc-I sialyltransferase localizes throughout the Golgi and is responsible for the synthesis of the tumor-associated sialyl-Tn O-glycan in human breast cancer. J Biol Chem 2006;281:3586-94.
(52.) Chiricolo M, Malagolini N, Bonfiglioli S, Dall'Olio F. Phenotypic changes induced by expression of beta-galactoside alpha2,6 sialyltransferase I in the human colon cancer cell line SW948. Glycobiology 2006;16:146-54.
(53.) Miyoshi E, Moriwaki K, Nakagawa T. Biological function of fucosylation in cancer biology. J Biochem 2008;143:725-9.
(54.) Kudo T, Ikehara Y, Togayachi A, Morozumi K, Watanabe M, Nakamura M, et al. Up-regulation of a set of glycosyltransferase genes in human colorectal cancer. Lab Invest 1998;78:797-811.
(55.) Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007; 98:621-8.
(56.) Murphy G. The ADAMs: signalling scissors in the tumour microenvironment. Nat Rev Cancer 2008;8:929-41.
(57.) Hojilla CV, Wood GA, Khokha R. Inflammation and breast cancer: metalloproteinases as common effectors of inflammation and extracellular matrix breakdown in breast cancer. Breast Cancer Res 2008;10:205.
(58.) Jezierska A, Motyl T. Matrix metalloproteinase-2 involvement in breast cancer progression: a mini-review. Med Sci Monit 2009;15:RA32-40.
(59.) Andre S, Kozar T, Kojima S, Unverzagt C, Gabius HJ. From structural to functional glycomics: core substitutions as molecular switches for shape and lectin affinity of N-glycans. Biol Chem 2009; 390:557-65.
(60.) Fuster MM, Esko JD. The sweet and sour of cancer: glycans as novel therapeutic targets. Nat Rev Cancer 2005;5:526-42.
(61.) Gahmberg CG, Fagerholm SC, Nurmi SM, Chavakis T, Marchesan S, Gronholm M. Regulation of integrin activity and signalling. Biochim Biophys Acta 2009;1790:431-44.
(62.) Gu J, Taniguchi N. Regulation of integrin functions by N-glycans. Glycoconj J 2004;21:9-15.
(63.) Isaji T, Sato Y, Fukuda T, Gu J. N-glycosylation ofthe I-like domain of beta1 integrin is essential for beta1 integrin expression and biological function: identification of the minimal N-glycosylation requirement for alpha5beta1. J Biol Chem 2009;284:12207-16.
(64.) Seales EC, Jurado GA, Brunson BA, Wakefield JK, Frost AR, Bellis SL. Hypersialylation of beta1 integrins, observed in colon adenocarcinoma, may contribute to cancer progression by upregulating cell motility. Cancer Res 2005;65: 4645-52.
(65.) Hedlund M, Ng E, Varki A, Varki NM. alpha 2-6-Linked sialic acids on N-glycans modulate carcinoma differentiation in vivo. Cancer Res 2008;68:388-94.
(66.) Ahmad N, Gabius HJ, Andre S, Kaltner H, Sabesan S, Roy R, et al. Galectin-3 precipitates as a pentamer with synthetic multivalent carbohydrates and forms heterogeneous cross-linked complexes. J Biol Chem 2004;279:10841-7.
(67.) Lagana A, Goetz JG, Cheung P, Raz A, Dennis JW, Nabi IR. Galectin binding to MGAT5-modified N-glycans regulates fibronectin matrix remodeling in tumor cells. Mol Cell Biol 2006; 26:3181-93.
(68.) Partridge EA, Le Roy C, Di Guglielmo GM, Pawling J, Cheung P, Granovsky M, et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science (Wash DC) 2004; 306:120-4.
(69.) Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer 2009;9:265-73.
(70.) Gout S, Tremblay PL, Huot J. Selectins and selectin ligands in extravasation of cancer cells and organ selectivity of metastasis. Clin Exp Metastasis 2008;25:335-44.
(71.) Psaila B, Lyden D. The metastatic niche: adapting the foreign soil. Nat Rev Cancer 2009;9: 285-93.
(72.) Rosen SD. Ligands for L-selectin: homing, inflammation, and beyond. Ann Rev Immunol 2004;22:129-56.
(73.) Witz IP. The selectin-selectin ligand axis in tumor progression. Cancer Metastasis Rev 2008; 27:19-30.
(74.) Thomas SN, Zhu F, Schnaar RL, Alves CS, Konstantopoulos K. Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow. J Biol Chem 2008;283: 15647-55.
(75.) Borsig L, Wong R, Feramisco J, Nadeau DR, Varki NM, Varki A. Heparin and cancer revisited: mechanistic connections involving platelets, P-selectin, carcinoma mucins, and tumor metastasis. Proc Natl Acad Sci USA 2001;98: 3352-7.
(76.) Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of L- and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis. Proc Natl Acad Sci USA 2002; 99:2193-8.
(77.) Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of tumor metastasis by expression of E-selectin in vivo. J Exp Med 1996; 183:581-7.
(78.) Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ. Lectin capture strategies combined with mass spectrometry for the discovery of serum glycoprotein biomarkers. Mol Cell Proteom 2006;5:1957-67.
(79.) Taniguchi N, Hancock W, Lubman DM, Rudd PM. The second golden age of glycomics: from functional glycomics to clinical applications. J Proteome Res 2009;8:425-6.
(80.) Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of the human plasma proteome comprising the top 4 logs of polypeptide abundance. Clin Chem 2008;54:1608-16.
(81.) Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, et al. Enhanced detection of low abundance human plasma proteins using a tandem IgY12-SuperMix immunoaffinity separation strategy. Mol Cell Proteom 2008;7:1963-73.
(82.) Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver B, et al. Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 2009;8:595-602.
(83.) Kullolli M, Hancock WS, Hincapie M. Preparation of a high-performance multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the analysis of human plasma glycoproteins. J Sep Sci 2008;31:2733-9.
(84.) Jung K, Cho W, Regnier FE. Glycoproteomics of plasma based on narrow selectivity lectin affinity chromatography. J Proteome Res 2009;8: 643-50.
(85.) Yang N, Li DF, Feng L, Xiang Y, Liu W, Sun H, Wang DC. Structural basis for the tumor cell apoptosis-inducing activity of an antitumor lectin from the edible mushroom Agrocybe ae gerita. J Mol Biol 2009;387:694-705.
(86.) Maley F, Trimble RB, Tarentino AL, Plummer TH Jr. Characterization of glycoproteins and their associated oligosaccharides through the use of endoglycosidases. Anal Biochem 1989;180:195-204.
(87.) Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al. Lectin affinity capture, isotope-coded tagging and mass spectrometry to identify N-linked glycoproteins. Nat Biotechnol 2003;21:667-72.
(88.) Xiong L, Andrews D, Regnier F. Comparative proteomics of glycoproteins based on lectin selection and isotope coding. J Proteome Res 2003;2:618-25.
(89.) Calvano CD, Zambonin CG, Jensen ON. Assessment of lectin and HILIC based enrichment protocols for characterization of serum glycoproteins by mass spectrometry. J Proteomics 2008; 71:304-17.
(90.) Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY. Identification of putative serum glycoprotein biomarkers for human lung adenocarcinoma by multilectin affinity chromatography and LC-MS/ MS. Proteomics 2007;7:4292-302.
(91.) Plavina T, Wakshull E, Hancock WS, Hincapie M. Combination of abundant protein depletion and multi-lectin affinity chromatography(M-LAC) for plasma protein biomarker discovery. J Proteome Res 2007;6:662-71.
(92.) Yang Z, Harris LE, Palmer-Toy DE, Hancock WS. Multilectin affinity chromatography for characterization of multiple glycoprotein biomarker candidates in serum from breast cancer patients. Clin Chem 2006;52:1897-905.
(93.) Cho W, Jung K, Regnier FE. Use of glycan targeting antibodies to identify cancer-associated glycoproteins in plasma of breast cancer patients. Anal Chem 2008;80:5286-92.
(94.) Yang Z, Hancock WS. Approach to the comprehensive analysis of glycoproteins isolated from human serum using a multi-lectin affinity column. J Chromatogr A 2004;1053:79-88.
(95.) Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, et al. Targeted glycoproteomic identification of biomarkers for human breast carcinoma. J Proteome Res 2008;7: 1470-80.
(96.) Lee YC, Block G, Chen H, Folch-Puy E, Foronjy R, Jalili R, et al. One-step isolation of plasma membrane proteins using magnetic beads with immobilized concanavalin A. Protein Expr Purif 2008;62:223-9.
(97.) Bond MR, Kohler JJ. Chemical methods for glycoprotein discovery. Curr Opin Chem Biol 2007; 11:52-8.
(98.) Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification of N-linked glycoproteins using hydrazide chemistry, stable isotope labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6.
(99.) Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H. Solid-phase extraction of N-linked glycopeptides. Nat Protoc 2007;2:334-9.
(100.) Sun B, Ranish JA, Utleg AG, White JT, Yan X, Lin B, Hood L. Shotgun glycopeptide capture approach coupled with mass spectrometry for comprehensive glycoproteomics. Mol Cell Proteomics 2007;6:141-9.
(101.) Sparbier K, Koch S, Kessler I, Wenzel T, Kostrzewa M. Selective isolation of glycoproteins and glycopeptides for MALDI-TOF MS detection supported by magnetic particles. J Biomol Tech 2005;16:407-13.
(102.) Sparbier K, Asperger A, Resemann A, Kessler I, Koch S, Wenzel T, et al. Analysis of glycoproteins in human serum by means of glycospecific magnetic bead separation and LC-MALDI-TOF/ TOF analysis with automated glycopeptide detection. J Biomol Tech 2007;18:252-8.
(103.) Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, et al. UniPep--a database for human N-linked glycosites: a resource for biomarker discovery. Genome Biol 2006;7:R73.
(104.) Laughlin ST, Bertozzi CR. Metabolic labeling of glycans with azido sugars and subsequent glycan-profiling and visualization via Staudinger ligation. Nat Protoc 2007;2:2930-44.
(105.) Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV. Glycomic profiling of invasive and noninvasive breast cancer cells. Glycoconj J 2009; 26:117-31.
(106.) Yamada K, Kinoshita M, Hayakawa T, Nakaya S, Kakehi K. Comparative studies on the structural features of O-glycans between leukemia and epithelial cell lines. J Proteome Res 2009;8:521-37.
(107.) Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S. Glycoproteomic analyses of ovarian cancer cell lines and sera from ovarian cancer patients show distinct glycosylation changes in individual proteins. J Proteome Res 2008;7: 3776-88.
(108.) Bereman MS, Williams TI, Muddiman DC. Development of a nanoLC LTQ orbitrap mass spectrometric method for profiling glycans derived from plasma from healthy, benign tumor control, and epithelial ovarian cancer patients. Anal Chem 2009;81:1130-6.
(109.) de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al. Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers 2008;25:243-58.
(110.) Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteom 2007;6:43-55.
(111.) Anderson L, Hunter CL. Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins. Mol Cell Proteomics 2006;5:573-88.
(112.) Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R, Domon B. High sensitivity detection of plasma proteins by multiple reaction monitoring of N-glycosites. Mol Cell Proteom 2007;6:1809-17.
(113.) Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009;27: 633-41.
(114.) Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson TW. Mass spectrometric quantitation of peptides and proteins using Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA). J Proteome Res 2004;3:235-44.
(115.) Ahn YH, Lee JY, Kim YS, Ko JH, Yoo JS. Quantitative analysis of an aberrant glycoform of TIMP1 from colon cancer serum by L-PHA-enrichment and SISCAPA with MRM mass spectrometry. J Proteome Res 2009;8:4216-24.
(116.) Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW. SISCAPA peptide enrichment on magnetic beads using an in-line bead trap device. Mol Cell Proteom 2009;8: 995-1005.
(117.) Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et al. Multiplexed analysis of glycan variation on native proteins captured by antibody microarrays. Nat Methods 2007;4:437-44.
(118.) Wu YM, Nowack D, Omenn G, Haab B. Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res 2009;8:1876-86.
(119.) Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
(120.) Presant CA, Kornfeld S. Characterization of the cell surface receptor for the Agaricus bisporus hemagglutinin. J Biol Chem 1972;247:6937-45.
(121.) Sueyoshi S, Yamamoto K, Osawa T. Carbohydrate binding specificity of a beetle (Allomyrina dichotoma) lectin. J Biochem 1988;103:894-9.
(122.) Ahmed H, Chatterjee BP. Further characterization and immunochemical studies on the carbohydrate specificity of jackfruit (Artocarpus integrifolia) lectin. J Biol Chem 1989;264:9365-72.
(123.) Kaladas PM, Kabat EA, Iglesias JL, Lis H, Sharon N. Immunochemical studies on the combining site of the D-galactose/N-acetyl-D-galactosamine specific lectin from Erythrina cristagalli seeds. Arch Biochem Biophys 1982;217:624-37.
(124.) Swamy MJ, Gupta D, Mahanta SK, Surolia A. Further characterization of the saccharide specificity of peanut (Arachis hypogaea) agglutinin. Carbohydr Res 1991;213:59-67.
(125.) Torres BV, McCrumb DK, Smith DF. Glycolipid lectin interactions: reactivity of lectins from Helix pomatia, Wisteria floribunda, and Dolichos biflorus with glycolipids containing N-acetylgalactosamine. Arch Biochem Biophys 1988;262:1-1 1.
(126.) Piller V, Piller F, Cartron JP. Comparison of the carbohydrate-binding specificities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur J Biochem 1990;191:461-6.
(127.) Roberts DD, Goldstein IJ. Reexamination of the carbohydrate binding stoichiometry of lima bean lectin. Arch Biochem Biophys 1984;230: 316-20.
(128.) Shen ZM, Shi WX, Sun C, Yang JT. Conformation and activity of mannose- and N-acetylgalactosamine-specific lectins from Vicia villosa seeds. Biochimie 1993;75:949-54.
(129.) Crowley JF, Goldstein IJ, Arnarp J, Lonngren J. Carbohydrate binding studies on the lectin from Datura stramonium seeds. Arch Biochem Biophys 1984;231:524-33.
(130.) Wood C, Kabat EA, Ebisu S, Goldstein IJ. An immunochemical study of the combining sites of the second lectin isolated from Bandeiraea simplicifolia (BS II). Ann Immunol (Paris) 1978;129: 143-58.
(131.) Nachbar MS, Oppenheim JD, Thomas JO. Lectins in the U.S. diet: isolation and characterization of a lectin from the tomato (Lycopersicon esculentum). J Biol Chem 1980;255:2056-61.
(132.) Allen AK, Neuberger A, Sharon N. The purification, composition and specificity of wheat-germ agglutinin. Biochem J 1973;131:155-62.
(133.) Peters BP, Ebisu S, Goldstein IJ, Flashner M. Interaction of wheat germ agglutinin with sialic acid. Biochemistry 1979;18:5505-11.
(134.) Yamamoto K, Tsuji T, Matsumoto I, Osawa T. Structural requirements for the binding of oligosaccharides and glycopeptides to immobilized wheat germ agglutinin. Biochemistry 1981;20: 5894-9.
(135.) Debray H, Decout D, Strecker G, Spik G, Montreuil J. Specificity of twelve lectins towards oligosaccharides and glycopeptides related to N-glycosylproteins. Eur J Biochem 1981;117:41-55.
(136.) Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B, Peumans WJ. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem 1987;262:1596-601.
(137.) Kornfeld K, Reitman ML, Kornfeld R. The carbohydrate-binding specificity of pea and lentil lectins. Fucose is an important determinant. J Biol Chem 1981;256:6633-40.
(138.) Debray H, Montreuil J. Aleuria aurantia agglutinin. A new isolation procedure and further study of its specificity towards various glycopeptides and oligosaccharides. Carbohydr Res 1989; 185:15-26.
(139.) Horejsi V, Ticha M, Kocourek J. Studies on lectins. XXXII. Application of affinity electrophoresis to the study of the interaction of lectins and their derivatives with sugars. Biochim Biophys Acta 1977;499:301- 8.
(140.) Pereira ME, Kabat EA. Specificity of purified hemagglutinin (lectin) from Lotus tetragonolobus. Biochemistry 1974;13:3184 -92.
(141.) Sughii S, Kabat EA, Baer HH. Further immunochemical studies on the combining sites of Lotus tetragonolobus and Ulex europaeus I and II lectins. Carbohydr Res 1982;99:99-101.
(142.) Ravindranath MH, Higa HH, Cooper EL, Paulson JC. Purification and characterization of an O-acetylsialic acid-specific lectin from a marine crab Cancer antennarius. J Biol Chem 1985;260: 8850-6.
(143.) Wang WC, Cummings RD. The immobilized leukoagglutinin from the seeds of Maackia amurensis binds with high affinity to complex-type Asn-linked oligosaccharides containing terminal sialic acid-linked alpha-2,3 to penultimate galactose residues. J Biol Chem 1988;263:4576-85.
(144.) Kolberg J, Michaelsen TE, Sletten K. Properties of a lectin purified from the seeds of Cicer arietinum. Hoppe Seylers Z Physiol Chem 1983; 364:655-64.
(145.) Petryniak J, Goldstein IJ. Evonymus europaea lectin. Methods Enzymol 1987;138:552- 61.
(146.) Cummings RD, Kornfeld S. Characterization of the structural determinants required for the high affinity interaction of asparagine-linked oligosaccharides with immobilized Phaseolus vulgaris leukoagglutinating and erythroagglutinating lectins. J Biol Chem 1982;257:11230-4.
(147.) Nemec M, Drimalova D, Horejsi V, Vanak J, Bartek J, Viklicky V. Murine monoclonal antibodies to human A erythrocytes: differential reactivity with N-acetyl-D-galactosamine. Vox Sang 1987;52:125-8.
(148.) Vanak J, Drimalova D, Smyslova O, Nemec M, Viklicky V, Wisniewski K. Detection of blood group A antigen expression in human colon cancer using monoclonal antibodies with different specificities. Neoplasma 1989;36:479-88.
(149.) Nystrom K, Grahn A, Lindh M, Brytting M, Mandel U, Larson G, Olofsson S. Virus-induced transcriptional activation of host FUT genes associated with neo-expression of Ley in cytomegalovirus-infected and sialyl-Lex in varicella-zoster virus-infected diploid human cells. Glycobiology 2007;17:355-66.
(150.) Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, et al. Summary report on the ISOBM TD-6 workshop: analysis of 20 monoclonal antibodies against Sialyl Lewisa and related antigens. Montreux, Switzerland, September 19-24, 1997. Tumour Biol 1998;19: 390-420.
(151.) Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response. Blood 2008;112:3661-70.
(152.) Lund-Johansen F, Olweus J, Horejsi V, Skubitz KM, Thompson JS, Vilella R, Symington FW. Activation of human phagocytes through carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65). J Immunol 1992;148:3221-9.
(153.) Mitsuoka C, Kawakami-Kimura N, Kasugai-Sawada M, Hiraiwa N, Toda K, Ishida H, et al. Sulfated sialyl Lewis X, the putative L-selectin ligand, detected on endothelial cells of high endothelial venules by a distinct set of anti-sialyl Lewis X antibodies. Biochem Biophys Res Commun 1997;230:546-51.
(154.) Yeh CY, Lin CN, Chang CF, Lin CH, Lien HT, Chen JY, Chia JS. C-terminal repeats of Clostridium difficile toxin A induce production of chemokine and adhesion molecules in endothelial cells and promote migration of leukocytes. Infect Immun 2008;76:1170-8.
(155.) Hemmerich S, Butcher EC, Rosen SD. Sulfation-dependent recognition of high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and adhesion-blocking monoclonal antibody. J Exp Med 1994;180:2219-26.
Penelope M. Drake,  Wonryeon Cho,  Bensheng Li,  Akraporn Prakobphol,  Eric Johansen,  N. Leigh Anderson,  Fred E. Regnier,  Bradford W. Gibson,  and Susan J. Fisher  *
 University of California San Francisco, San Francisco, CA;  Purdue University, West Lafayette, IN;  Buck Institute for Age Research, Novato, CA;  Plasma Proteome Institute, Washington, DC.
 Nonstandard abbreviations: MS, mass spectrometry; CEA, carcinoembryonic antigen; CA-125, cancer antigen 125; PSA, prostate-specific antigen; [sLe.sup.a], [sialyl Lewis.sup.a]; HPA, Helix pomatia agglutinin; UEA 1, Ulex europaeus I; GlcNAcT-V, UDP-GlcNAc:N-glycan GlcNAc transferase V; MMP, matrix metalloproteinase; ADAM, a disintegrin and metalloproteinase; ECM, extracellular matrix; EGF, epidermal growth factor; EGFR, EGF receptor; T[beta]R, transforming growth factor [beta] receptor; LC-MS/MS, liquid chromatography-tandem mass spectrometry; PNGase, peptide N-glycosidase; AAL, Aleuria aurantia lectin; LCA, Lens culinaris agglutinin; LEL, Lycopersiconesulentum lectin; MRM, multiple reaction monitoring; SISCAPA, stable isotope standards and capture by antipeptide (or anticarbohydrate) antibodies; MUC1, mucin-1.
 Human genes: FUT2, fucosyltransferase 2 (secretor status included) (alias, galactoside 2-[alpha]-L-fucosyltransferase 2); FUT3, fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group); MGAT5, mannosyl ([alpha]-1,6-)-glycoprotein [beta]-1,6-N-acetyl-glucosaminyltransferase.
* Address correspondence to this author at: 513 Parnassus Ave., Box 0556, San Francisco, CA 94143. Fax 415-502-7338; e-mail firstname.lastname@example.org.
Received August 30, 2009; accepted October 30, 2009.
Previously published online at DOI: 10.1373/clinchem.2009.136333
Table 1. Specificities of lectins and carbohydrate-reactive antibodies. Detection reagent and Lectin or antibody Carbohydrate general reactivity structural motif Lectin [alpha][beta]-D Agaricus bisporus Gal[beta]1-3GalNAc -Galactosyl (ABA) -serine/threonine specific Allomyrina NeuAc[alpha]2-3Gal dichotoma (AlloA) [beta]1-4GlcNAc Artocarpus Gal[beta]1-3GalNAc, integrifolia Gal[alpha]1-6Gal (Jacalin) Erythrina Gal[beta]1 christagalli(ECA) -4GlcNAc Arachis hypogaea Gal[beta]1-3GalNAc (peanut, PNA) D-N Dolichos biflorus GalNAc[alpha]1 -Acetylgalactosaminyl (DBA) -3GalNAc specific GalNAc[alpha]1-3Gal Glycine max GalNAc[alpha]1 (soybean, SBA) -3GalNAc GalNAc [alpha][beta] 1-3/4Gal Helix pomatia [alpha]-GalNAc, (HPA) GalNAc[beta]1-4Gal Phaseolus lunatus GalNAc[alpha]1-3 (lima bean, LBA) (Fuc[alpha]1-2) Gal[beta] GalNAc[alpha] 1-2Gal[beta] Wisteria GalNAc[alpha] floribunda (WFA) 1-3GalNAc GalNAc [beta]1-3/4Gal Vicia villosa GalNAc-Ser (VVA) D-N Datura stramonium [(GlcNAc[beta]1-4) -Acetylglucosamine (DSA) .sub.2-4], specific Gal[beta]1-4GlcNAc Griffonia GlcNAc[alpha]1-4Gal simplifilica II [beta]1-4GlcNAc (GS-II) Lycopersicon [(GlcNAc[beta] esculentum 1-4).sub.1-4] (Tomato) Triticum vulgare [(GlcNAc[beta] (wheat germ, WGA) 1-4).sub.2-5], Neu5Ac Man[beta]1-4GlcNAc [beta]1-4GlacNAc D-Mannosyl specific Canavalia Branched N-linked ensiformis (Con A) hexa-saccharide Galanthus Man[alpha]1-3Man nivalis (GNA) Lens culinaris Fuc[alpha]1-6GlcNAc (LCA) -N-Asn containing N-linked oligosaccharides Pisum sativum Fuc[alpha]1-6GlcNAc (PSA) -N-Asn containing N-linked oligosaccharides [alpha]-L-Fucosyl Aleuria aurantia Fuc[alpha]1-6[beta] specific (AAL) GlcNAc Anguilla [alpha]-L-Fuc anguilla (AAA) Lotus Fuc[alpha]1-2Gal tetragonolobus [beta]1-4 (LCA) (Fuc[alpha]1-3) GlcNAc Ulex europaeus Fuc[alpha]1 I (UEA I) -2Gal[beta] Neu5Ac specific Cancer 4/9-O-Ac-Neu5Ac antennarius (CAA) Maackia amurensis Neu5Ac[alpha]2-3Gal II (MAA II) [beta]1-4Glc/GlcNAc Sambucus nigra Neu5Ac[alpha]2 (SNA) -6Gal/GalNAc Lectins with Cicer arietinum Complex structure, complex specificities (CPA) binding inhibited by human IgM, fetuin Euonymus Gal[alpha]1 europaeus (EEA) -3(Fuc[alpha]1-2)Gal [beta]1-3/4GlcNAc Phaseolus N-linked vulgaris bi-antennary erythroagglutinating (PHA-E) Phaseolus vulgaris N-linked leukoagglutinating tri/tetra-antennary (PHA-L) Antibody Lewis and ABH Anti-blood group O (Fuc[alpha]1-2) blood group antigens (H) Gal[beta]1-3/ 4GlcNAc Anti-blood group A GalNAc[alpha]1-3 (Fuc[alpha]1-2)Gal Anti-blood group B Gal[alpha]1-3 (Fuc[alpha]1-2)Gal [Anti-Lewis.sup.a] Gal[beta]1-3 (anti-Le (a)) (Fuc[alpha]1-4) GlcNAc Anti-sialylated NeuAc[alpha]2 [Lewis.sup.a] -3Gal[beta]1-3 ([anti-sLe.sup.a]) (Fuc[alpha]1-4) GlcNAc [Anti-Lewis.sup.b] Fuc[alpha]1-2Gal ([anti-Le.sup.b]) [beta]1-3 (Fuc[alpha]1-4) GlcNAc [Anti-Lewis.sup.x] Gal[beta]1-4 ([anti-Le.sup.x], (Fuc[alpha]1-3) CD15) GlcNAc Anti-sialylated NeuAc[alpha]2 [Lewis.sup.x] -3Gal[beta]1-4 ([anti-sLe.sup.x], (Fuc[alpha]1-3) CSLEX-1) GlcNAc [Anti-Lewis.sup.y] Fuc[alpha]1 ([anti-Le.sup.y]) -2Gal[beta]1-4 (Fuc[alpha]1-3) GlcNAc HECA-452 NeuAc[alpha]2 -3Gal[beta]1-4 (Fuc[alpha]1-3) GlcNAc NeuAc[alpha]2 -3Gal[beta]1-4 (Fuc[alpha]1-3) (SO3-6)GlcNAc, NeuAc[alpha]2-3 (SO3-6)Gal[beta]1-4 (Fuc[alpha]1-3) GlcNAc NeuAc[alpha]2-3 (SO3-6)Gal[beta]1-4 (Fuc[alpha]1-3) (SO3-6)GlcNAc MECA-79 Complex structure containing SO3-6GlcNAc Detection reagent and Lectin or antibody References general reactivity Lectin [alpha][beta]-D Agaricus bisporus Presant and -Galactosyl (ABA) Kornfeld (120) specific Allomyrina Sueyoshi et al. dichotoma (AlloA) (121) Artocarpus Ahmed and integrifolia Chatterjee (122) (Jacalin) Erythrina Kaladas et al. christagalli(ECA) (123) Arachis hypogaea Swamy et al. (124) (peanut, PNA) D-N Dolichos biflorus Torres et al. (125) -Acetylgalactosaminyl (DBA) specific Piller et al. (126) Glycine max Piller et al. (126) (soybean, SBA) Helix pomatia Torres et al. and (HPA) Piller et al. (125, 126) Phaseolus lunatus Roberts and (lima bean, LBA) Goldstein (127) Wisteria Torres et al. (125) floribunda (WFA) Piller et al. (126) Vicia villosa Shen et al. (128) (VVA) D-N Datura stramonium Crowley et -Acetylglucosamine (DSA) al. (129) specific Griffonia Wood et al. (130) simplifilica II (GS-II) Lycopersicon Nachbaretal. (131) esculentum (Tomato) Triticum vulgare Allen et al. and (wheat germ, WGA) Peters et al. (132, 133) Yamamoto et al. (134) D-Mannosyl specific Canavalia Debray et al. (135) ensiformis (Con A) Galanthus Shibuya et nivalis (GNA) al. (136) Lens culinaris Debray et al. (135) (LCA) Pisum sativum Debray et al. (135) (PSA) [alpha]-L-Fucosyl Aleuria aurantia Kornfeld et specific (AAL) al. (137) Anguilla Debray and anguilla (AAA) Montreuil (138) Lotus Horejsi et tetragonolobus al. (139) (LCA) Ulex europaeus Pereira and I (UEA I) Kabat (140) Neu5Ac specific Cancer Sughii etal. (141) antennarius (CAA) Maackia amurensis Ravindranath et II (MAA II) al. (142) Sambucus nigra Wang and (SNA) Cummings (143) Lectins with Cicer arietinum Kolberg et complex specificities (CPA) al. (144) Euonymus Petryniak and europaeus (EEA) Goldstein (145) Phaseolus Cummings and vulgaris Kornfeld (146) erythroagglutinating (PHA-E) Phaseolus vulgaris Cummings and leukoagglutinating Kornfeld (146) (PHA-L) Antibody Lewis and ABH Anti-blood group O Nemec et al. (147) blood group antigens (H) Anti-blood group A Nemec et al. (147) Anti-blood group B Vanak et al. (148) [Anti-Lewis.sup.a] Nystrom et (anti-Le (a)) al. (149) Anti-sialylated Rye et al. (150) [Lewis.sup.a] ([anti-sLe.sup.a]) [Anti-Lewis.sup.b] Shi etal. (151) ([anti-Le.sup.b]) [Anti-Lewis.sup.x] Lund-Johansen ([anti-Le.sup.x], et al. (152) CD15) Anti-sialylated Mitsuoka et [Lewis.sup.x] al. (153) ([anti-sLe.sup.x], CSLEX-1) [Anti-Lewis.sup.y] Yeh et al. (154) ([anti-Le.sup.y]) HECA-452 Mitsuoka et al. (153) MECA-79 Hemmerich et al. (155)